Otonomy names new CMO
This article was originally published in Scrip
Otonomy, a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for disorders of the inner and middle ear, has named Dr Dean Hakanson chief medical officer. Dr Hakanson has more than 16 years of industry experience in medical affairs, market access and health economic research with pharmaceutical companies including Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline. He joins Otonomy from Novartis, where he was most recently vice-president and head of health economics and outcomes research (HE&OR) for US medical and drug regulatory affairs.